The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2018 | bb2121: a promising outlook for the future of multiple myeloma
The CRB-401 trial (NCT02658929) aims to investigate the efficacy of idecabtagene vicleucel (formerly bb2121) for multiple myeloma (MM) patients. In this interview, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Howard Burris, MD, FACP, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, outlines the preliminary results of the trial and speaks about the possible advances that could be made as a result.
